Opposing Tumor-Promoting and -Suppressive Functions of Rictor/mTORC2 Signaling in Adult Glioma and Pediatric SHH Medulloblastoma.

Seçkin Akgül
Yinghua Li
Siyuan Zheng
Marcel Kool
Daniel M Treisman

See next page for additional authors

Follow this and additional works at: https://mouseion.jax.org/stfb2018

Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons

Recommended Citation
Akgül, Seçkin; Li, Yinghua; Zheng, Siyuan; Kool, Marcel; Treisman, Daniel M; Li, Chaoyang; Wang, Yuan; Gröbner, Susanne; Ikenoue, Tsuneo; Shen, Yiping; Camelo-Piragua, Sandra; Tomasek, Gerald; Stark, Sebastian; Guduguntla, Vinay; Gusella, James F; Guan, Kun-Liang; Pfister, Stefan M; Verhaak, Roel G W; and Zhu, Yuan, "Opposing Tumor-Promoting and -Suppressive Functions of Rictor/mTORC2 Signaling in Adult Glioma and Pediatric SHH Medulloblastoma." (2018). Faculty Research 2018. 148.
https://mouseion.jax.org/stfb2018/148

This Article is brought to you for free and open access by the Faculty Research at The Mouseion at the JAXlibrary. It has been accepted for inclusion in Faculty Research 2018 by an authorized administrator of The Mouseion at the JAXlibrary. For more information, please contact ann.jordan@jax.org.
Opposing Tumor-Promoting and -Suppressive Functions of Rictor/mTORC2 Signaling in Adult Glioma and Pediatric SHH Medulloblastoma

Graphical Abstract

Highlights
- p53-mutant-driven gliomas acquire chromosomal alterations of adult primary GBM
- Rictor/mTORC2 loss delays glioma formation and prolongs survival
- Rictor deletion with p53 loss promotes SHH-MB formation from GCPs
- Low Rictor expression is associated with poor survival of human pediatric SHH-MBs

Authors
Sec¸kin Akgül, Yinghua Li, Siyuan Zheng, ..., Stefan M. Pfister, Roel G.W. Verhaak, Yuan Zhu

Correspondence
yzhu@childrensnational.org

In Brief
Hyperactivation of PI3K/AKT signaling is frequently observed in adult glioblastomas (GBMs), whereas sonic hedgehog-subgroup medulloblastomas (SHH-MBs) in children rarely exhibit AKT activation. Using a genetically engineered mouse model of malignant brain tumor, Akgül et al. show that Rictor/mTORC2 loss inhibits Akt signaling, which delays p53-mutant-driven malignant gliomas, while promoting SHH-MBs.

Akgül et al., 2018, Cell Reports 24, 463–478
July 10, 2018 © 2018 The Author(s).
https://doi.org/10.1016/j.celrep.2018.06.050
Owing Tumor-Promoting and -Suppressive Functions of Rictor/mTORC2 Signaling in Adult Glioma and Pediatric SHH Medulloblastoma

Seçkin Akgül, Yinghua Li, Siyuan Zheng, Marcel Kool, Daniel M. Treisman, Chaoyang Li, Yuan Wang, Susanne Gröbner, Tsuneo Ikenoue, Yiping Shen, Sandra Camelo-Piragua, Gerald Tomasek, Sebastian Stark, Vinay Guduguntla, James F. Gusella, Kun-Liang Guan, Stefan M. Pfister, Roel G.W. Verhaak, and Yuan Zhu

1Cellular and Molecular Biology Graduate Program, University of Michigan Medical School, Ann Arbor, MI 48109, USA
2Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA
3Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
4Gilbert Family Neurofibromatosis Institute, Children’s National Medical Center, Washington, DC 20010, USA
5Center for Cancer and Immunology Research, Children’s National Medical Center, Washington, DC 20010, USA
6Center for Neuroscience Research, Children’s National Medical Center, Washington, DC 20010, USA
7Greehey Children’s Cancer Research Institute, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
8Hopp Children’s Cancer Center at the NCT Heidelberg (KITZ), 69120 Heidelberg, Germany
9Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany
10Department of Pharmacology and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92037, USA
11Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
12Department of Pathology and Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany
13Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA
14Sid Faithfull Brain Cancer Research Laboratory, Cell & Molecular Biology Department, QIMR Berghofer Medical Research Institute, Brisbane 4006, Australia
15These authors contributed equally
16Lead Contact

*Correspondence: yzhu@childrensnational.org
https://doi.org/10.1016/j.celrep.2018.06.050

SUMMARY

Most human cancers arise from stem and progenitor cells by the sequential accumulation of genetic and epigenetic alterations, while cancer modeling typically requires simultaneous multiple oncogenic events. Here, we show that a single p53 mutation, despite causing no defect in the mouse brain, promoted neural stem and progenitor cells to spontaneously accumulate oncogenic alterations, including loss of multiple chromosomal (chr) regions syntenic to human chr10 containing Pten, forming malignant gliomas with PI3K/Akt activation. Rictor/mTORC2 loss inhibited Akt signaling, greatly delaying and reducing glioma formation by suppressing glioma precursors within the subventricular zone stem cell niche. Rictor/mTORC2 loss delayed timely differentiation of granule cell precursors (GCPs) during cerebellar development, promoting sustained GCP proliferation and medulloblastoma formation, which recapitulated critical features of TP53 mutant sonic hedgehog (SHH) medulloblastomas with GLI2 and/or N-MYC amplification. Our study demonstrates that Rictor/mTORC2 has opposing functions in neural stem cells and GCPs in the adult and the developing brain, promoting malignant gliomas and suppressing SHH-medulloblastoma formation, respectively.

INTRODUCTION

More than 90% of human glioblastomas (GBMs) are primary or de novo GBMs with no evidence of pre-existing lower-grade lesions (Louis et al., 2016). Rapid clinical course presents a tremendous challenge in defining the temporal sequence and functional outcomes of accumulating each of the oncogenic driver alterations in neural stem or progenitor cells during the development of primary GBMs. One recent study using a bioinformatics approach inferred that most somatic TP53 mutations (90.5%) were clonal, occurring in every tumor cell of the GBM samples analyzed and thus representing one of the early finding events in TP53 mutant primary GBMs (Kim et al., 2015). Moreover, individuals with Li-Fraumeni syndrome (LFS) carrying germline TP53 mutations have increased risks of developing malignant gliomas and GBMs as well as medulloblastomas (MBs), the most common malignant brain tumor in children (Louis et al., 2016). Consistent with an initiating role of TP53 mutations in human brain tumorigenesis, conditional inactivation of p53 in the mouse brain induces malignant gliomas and GBMs and, less frequently, MBs (Wang et al., 2009; Zheng et al., 2008). Both clinical observations and mouse modeling studies suggest...
Figure 1. p53-Mutant Malignant Gliomas Exhibit Unique Genomic Alterations Consistent with Human Primary GBMs

(A and B) Gene expression profiles of the p53-mutant-driven malignant gliomas with or without targeted Nf1 deletions are compared to those of human GBM subgroups (A) and different cell lineages in the brain (B). High single-sample gene set enrichment analysis (ssGSEA) score (red) indicates strong similarity, while low scores (blue) indicate dissimilarity. FB, forebrain; CB, cerebellum.

(C and D) The GISTIC method was used to detect both local and broad CNAs in 23 GEM malignant gliomas. GISTIC scores and FDRs are indicated in the upper and lower parts of the x axes, respectively. Chromosomal regions with amplification peaks (C) or deletion peaks (D) are listed. Some frequently amplified and deleted genes in both GEM malignant gliomas and TP53 mutant human GBMs are highlighted in red and blue, respectively.

(E) Synteny map comparing the human chr10q with the mouse chr19 and chr7.

(F) syntenic to human chr19

(G) Syntenic to human chr10q

(legend continued on next page)
that p53 plays a critical role in the initiation of both GBMs and MBs. However, loss of p53 alone leads to little or no effect on the mouse brain during development or in adulthood (Chow et al., 2011; Shingu et al., 2017; Wang et al., 2009; Zheng et al., 2008). Therefore, this conditional neural-specific p53-mutant model must accumulate cooperating oncogenic alterations in cells with sustained proliferative potentials—neural stem or progenitor cells—to drive malignant transformation in the brain (Innie and Alvarez-Buylla, 2011; Wang et al., 2009, 2012).

Loss of the long arm of chromosome 10 (chr10q) appears to be a common mechanism, occurring in almost all primary GBMs, but less frequently in secondary GBMs that arise from pre-existing lower-grade gliomas harboring isocitrate dehydrogenase 1 (IDH) mutations (Brennan et al., 2013; Louis et al., 2016; Sturm et al., 2014). Although loss of a relatively large region of chr10q suggests the existence of multiple tumor-suppressor genes, the most studied is the PTEN tumor suppressor, which negatively regulates the phosphoinositide 3-kinase (PI3K) signaling pathway (Janku et al., 2018; Ozawa et al., 2014). Loss of PTEN in chr10q is consistent with the observation that most GBMs in humans (>80%) exhibit activation of AKT signaling, the best characterized downstream effector of the PI3K/PTEN signaling pathway (Janku et al., 2018; Wang et al., 2004). AKT requires two phosphorylation events for full activation: (1) PDK1 phosphorylates AKT at threonine-308 (AKTThr308) and (2) the mechanistic target of rapamycin complex 2 (mTORC2) is the major kinase that phosphorylates AKT at serine-473 (AKTSer473) (Janku et al., 2018; Laplante and Sabatini, 2012; Wu et al., 2014). Given its critical functions on metabolic reprogramming and drug resistance, mTORC2 has recently been emerging as an attractive therapeutic target for human GBMs (Masui et al., 2013, 2015; Wu et al., 2014). It has been shown that loss of RICTOR/Rictor, an essential subunit of mTORC2, is sufficient to inhibit phosphorylation of AKT/Akt at serine-473, inactivate AKT/Akt, and, consequently, prevent tumor formation in several Pten-loss-driven mouse cancer models, including prostate cancer and leukemia, as well as in a Drosophila glioma model (Guertin et al., 2009; Kalaitzidis et al., 2012; Magee et al., 2012; Read et al., 2009), However, whether Rictor/mTORC2 signaling in neural stem or progenitor cells is required for the formation of primary GBM remains to be determined.

In contrast to GBMs, mutations in PTEN or other components of the PI3K signaling pathway are rare in MBs, and more important, almost no phosphorylated AKTSer473 (<5%) was observed in pediatric sonic hedgehog-MBs (SHH-MBs), the only MB subtype observed in individuals with LFS (Kool et al., 2014; Northcott et al., 2012). These intriguing observations raise the possibility of whether mTORC2/AKT signaling has opposing effects on the formation of TP53 mutant primary GBMs versus SHH-MBs.

RESULTS

p53-Mutant GEM Gliomas Spontaneously Acquire Common Genomic Alterations Observed in Human Primary GBMs

Using a Cre transgenic line controlled by the human glial fibrillary acidic protein promoter (hGFAP-cre), we previously developed three genetically engineered mouse (GEM) glioma models driven by a conditional in-frame deletion of exons 5 and 6 of the p53 gene (1) alone (hGFAP-cre;p53E5–6/E5–6) or (2) in combination with a germline heterozygous neurofibromatosis type 1 (Nf1) mutation (hGFAP-cre;p53E5–6/E5–6,Nf1+/−), and (3) a germline p53 null and a conditional Nf1 mutation on the same chromosome (hGFAP-cre; cis:p53−/−;Nf1+/−/+loxP) (Wang et al., 2009, 2012; Zhu et al., 2005). All three GEM models frequently developed malignant gliomas, which harbor homozygous p53 deletion with or without additionally targeted Nf1 deletion, hereafter referred to as p53E5–6/E5–6,Nf1+/− and p53−/−;Nf1+/−, respectively. These malignant gliomas exhibited critical pathophenotypic characteristics of human high-grade gliomas (grades III and IV), including nuclear atypia and frequent mitotic figures, with approximately 40% showing necrosis and/or microvascular proliferation, the diagnostic features of human GBM (Louis et al., 2016; Wang et al., 2009; Zhu et al., 2005).

The gene expression profiles of all but two of the p53−/−;Nf1+/− malignant gliomas exhibited a dominant proneural signature of human GBMs (Figure 1A) (Verhaak et al., 2010). The two exceptions with a classical signature uniquely exhibited EGFR amplification on chr11 (human chr7), similar to most of the human classical GBMs with EGFR alterations (Figures 1A and S1A–S1C) (Verhaak et al., 2010). Sanger sequencing did not reveal somatic mutations of Idh1 or Idh2 in these GEM gliomas (n = 7). The gene expression profiles of these gliomas did not consistently resemble IDH mutant GBMs with a hypermethylated phenotype or glioma CpG island methylated phenotype (G-CIMP) (Figure 1A) (Baysan et al., 2012; Noushmehr et al., 2010; Ozawa et al., 2014). Together, these results demonstrate that p53- and p53/Nf1-mutant-driven malignant gliomas genetically and molecularly resemble the proneural subtype of IDH-wild-type (IDH-WT) primary GBMs, but not IDH mutant G-CIMP+ secondary GBMs in humans.

To determine oncogenic driving events during p53- and p53/Nf1-mutant-driven gliomagenesis, we analyzed the copy-number alterations (CNAs) in a total of 23 malignant gliomas and GBMs. We applied Genomic Identification of Significant Targets in Cancer (GISTIC) analysis, a de facto community standard for characterizing local and broad CNAs in human cancers (Mermel et al., 2012). Therefore, this conditional neural-specific p53-mutant model must accumulate cooperating oncogenic alterations in cells with sustained proliferative potentials—neural stem or progenitor cells—to drive malignant transformation in the brain (Innie and Alvarez-Buylla, 2011; Wang et al., 2009, 2012).
Figure 2. Rictor Deletion Inhibits p53-Mutant-Driven Malignant Glioma Formation

(A and B) Kaplan-Meier survival curves of mice sacrificed because of end-stage brain tumors (A) or end-stage malignant gliomas (B) in three models. Black dashed line indicates 1 year. Red dashed-line box in (A) indicates a comparable survival rate.

(C) The frequency of malignant gliomas and MBs.

(D and E) Mutant mice at age 6–7 months were injected with BrdU for proliferation assay. Expansion of the glioma precursor population around the corpus callosum (D) and rostral migratory stream (E) is illustrated by p53 and BrdU staining. Yellow dashed-line area indicates the p53 \(D_{5-6}^+\) cluster. Ctx, cerebral cortex; CC, corpus callosum; OB, olfactory bulb; RMS, rostral migratory stream; LV, lateral ventricle.

(legend continued on next page)
et al., 2011). We found that both GEM p53-mutant gliomas and human TP53-mutant GBMs exhibited significantly fewer amplifications than deletions (false discovery rate [FDR] 0.25) (Figures 1C, 1D, S1D, and S1E). In GEM gliomas, approximately 1% and 16% of the genome (excluding the sex chromosome) was affected by amplifications and deletions, respectively. This pattern is remarkably similar to that observed in human TP53 mutant IDH-WT GBMs—1% and 12% of the genome affected by amplifications and deletions, respectively. All 17 amplification peaks identified in GEM gliomas across chr4, -6, -7, -12, and -14 were focal (14/17 <2 MBs), a pattern reminiscent of human GBMs (Figure 1C; Table S1) (Brennan et al., 2013). Cross-referencing with human data, we found a peak in chr6 syntenic to human chr7, the most frequently gained chromosome in human IDH-WT but not IDH mutant GBMs (Figures 1C, S1A, and S1D). The chr6 amplicon encompassed Met, amplified in three cases. Other significant oncogenes in the amplification peaks included Ccnd1 and Ccnd2 (Figure 1C; Table S1). Of note, GISTIC analysis did not identify a peak centering on Egfr, which is also syntenic to human chr7, but it was amplified in only two cases without Met amplification and identified by a targeted approach (Figures S1A–S1C). These results suggest that individual GEM p53-mutant gliomas acquire different oncogenic alterations, including Met or Egfr, driving malignant transformation following p53 inactivation (Figure S1B).

Deletions in these GEM gliomas were largely contributed by broad losses of chr7, -9, and -19 (Figures 1D, S1D, and S1E). Because mouse and human chromosomes are often not syntenic, loss of chr9 was deleted in 13/23 GEM gliomas (57%) but mapped to multiple human chromosomal regions, including chr11q, -19p, -15q, -6q, and -3. Among them, chr11q was deleted in 30% of human GBMs, and other syntenic regions were also deleted, but less frequently (Brennan et al., 2013). Loss of chr10q, the most frequent broad event found in >90% of IDH-WT GBMs, is mapped into multiple mouse chromosomes, including chr19 and the distal end of chr7 (Figures 1E, 1F, and S1D). It was most striking that the deletion of chr19, the distal end of chr7, or both were observed in 70%, 78%, or 65% of the 23 GEM gliomas analyzed, respectively, thus recapitulating one of the most prevalent chromosomal abnormalities in human IDH-WT GBMs (Figures 1D–1F, S1D, and S1E). We further used qPCR analysis on an independent cohort of 11 p53\(^{-}\)/mutant-driven malignant gliomas, of which 82%, 73%, and 55% exhibited the loss of chr19, the distal end of chr7, and both, respectively (Figure 1G). These results demonstrate that the majority of p53\(^{3/4}\), mutant-driven malignant gliomas, regardless of the absence or presence of the NFI mutation, exhibit concurrent loss of chr19 and the distal end of chr7, both of which are syntenic to human 10q.

When a conditional heterozygous Pten mutation with a floxed exon 5 (Pten\(^{1E/5}\)) was introduced to the p53\(^{3/4}\) model, the resultant p53\(^{3/4}\)-mutant-driven gliomas exhibitedCre-mediated deletion of exon 5 but not unfloxed exon 9 (Figure 1H) (Zheng et al., 2008). In contrast, the p53-mutant-driven gliomas exhibited a reduction in both exons 5 and 9 of the Pten gene as a result of chr19 loss, which was predicted by both GISTIC and raw CNA data (Figure 1H). Similarly, high-grade malignant gliomas induced by conditional inactivation of p53 and Pten (with or without Rb) also did not exhibit the chr19 loss reported in a previous study (Figure S1F) (Chow et al., 2011). These results demonstrate that targeted deletion of Pten abrogates chr19 loss, thus circumventing the selection of malignant glioma cells with a hallmark of chromosomal abnormalities (chr10q loss) in human primary GBMs.

**Rictor/mTORC2 Deletion Delays p53-Mutant-Driven Malignant Glioma Formation**

Given the frequent loss of chr19/Pten and the activation of the PI3K/Akt signaling pathway in these GEM malignant gliomas, we analyzed the effects of the conditional loss of one or two alleles of Rictor in the p53\(^{3/4}\)-mutant brain tumor model (hereafter referred to as p53\(^{3/4}\)-Rictor\(^{-/}\) or p53\(^{3/4}\)-Rictor\(^{+/}\), compared to p53\(^{3/4}\)-mutant mice) (Figure S3C). The loss of both alleles, not one allele of Rictor, significantly prolonged the lifespan of p53\(^{3/4}\)-mutant mice with brain tumors (Figure 2A). Prolonged lifespan (>50%) and long-term survivors (>12 months) were predominantly observed in p53\(^{3/4}\)-Rictor\(^{+/}\) mice, which mainly resulted from a delay in the formation of malignant gliomas and tumors outside the brain (Figures 2B, S2A, and S2B). The majority of brain tumors were characterized as high-grade malignant astrocytic gliomas, including GBMs with expression of GFAP and Olig2, as well as high levels of p53\(^{+/}\)-mutant protein (Figures 2C and S2C) (Louis et al., 2010). These results demonstrate that Rictor deletion extends survival by delaying p53\(^{3/4}\), mutant-driven malignant glioma formation.

We have previously provided evidence that all malignant gliomas specifically accumulate high levels of mutant p53\(^{3/4}\)-protein, which appear to arise from p53\(^{3/4}\)-glioma precursor cells that emerge from the subventricular zone (SVZ) stem cell niche at ~4–7 months of age (Ihrie and Alvarez-Buylla, 2011; Wang et al., 2009). Highly proliferating cell clusters expressing high levels of p53\(^{3/4}\)-protein were consistently identified in the corpus callosum, the rostral migratory stream, and the olfactory bulb—the areas associated with the SVZ stem cell niche, in 5 of 9 p53\(^{3/4}\)-mutant brains analyzed at 6–7 months of age (Figures 2D–2F). In contrast, only 1 of 9 age-matched p53\(^{3/4}\)-Rictor\(^{+/}\) brains had a similar p53\(^{3/4}\)-/bromodeoxyuridine-positive (BrdU\(^{+}\)) cluster, which exhibited a significantly lower proliferation

(F and G) The total number of the p53\(^{3/4}\)- cells scattered and/or clustered outside the germinal zone was quantified in p53\(^{3/4}\)-/ and p53\(^{3/4}\)-Rictor\(^{+/}\) mice (F). The percentage of the proliferating p53\(^{3/4}\)- cells was calculated using the samples that have ≥20 p53\(^{3/4}\)-/ cells (G).

(H and I) Western blot analyses of malignant gliomas from different GEM models. Normal cortical tissue was used as control (CTR), and two malignant gliomas that harbored p53 and Pten mutations (described in Figure S3D) were included. All of the quantification data are presented as means ± SEMs. The Mantel-Cox (log-rank) test was used to compare the survival curves (A and B). Two-tailed Fisher's exact test was used to compare the groups (C and G). Scale bars: 250 μm (D and E) and 50 μm (H).

See also Figure S2.
rate than those in the clusters of p53\(^{\Delta S/\Delta S}\)- brains (Figures 2F and 2G). Furthermore, p53\(^{\Delta S/\Delta S}\) glioma precursor cells were largely restricted within the SVZ of this p53\(^{\Delta S/\Delta S}\)-Rictor\(^{-}\)A brain, whereas glioma precursors were widely distributed in surrounding areas of the SVZ of p53\(^{\Delta S/\Delta S}\)- brains (Figures 2D, 2E, and S2D). Loss of both Rictor alleles also significantly reduced the proliferation rate in malignant gliomas analyzed at end stages (Figures 2H and 2I). These results demonstrate that Rictor/mTORC2 loss inhibits both tumor initiation and progression, thereby prolonging the survival of p53\(^{\Delta S/\Delta S}\)-Rictor\(^{-}\)A mice with malignant gliomas.

We confirmed that all malignant gliomas only expressed the recombined p53\(^{\Delta S/\Delta S}\) alleles, and both floxed Rictor alleles were recombined in the p53\(^{\Delta S/\Delta S}\)-Rictor\(^{-}\)A gliomas (Figure S2E). Consistent with human GBMs, almost all Rictor-proficient gliomas in p53\(^{\Delta S/\Delta S}\)- and p53\(^{\Delta S/\Delta S}\)-Rictor\(^{-}\)A mice exhibited robust expression of phosphorylated pAkt\(^{T308}\) and pAkt\(^{S473}\), accompanied by the loss of Pten expression (Figures 2J and S2F). In contrast, Rictor-deficient gliomas in p53\(^{\Delta S/\Delta S}\)-Rictor\(^{-}\)A mice showed little or no pAkt\(^{T308}\) and pAkt\(^{S473}\) expression without altering the total level of Akt (Figure 2J). The phosphorylation of Ndr1 by another mTORC2 substrate, SGK1, was also significantly reduced in Rictor-deficient gliomas compared to Rictor-proficient gliomas (Figure 2J). These results demonstrate that Rictor deletion almost completely abolishes the mTORC2 activity for the phosphorylation of Akt\(^{T308}\) and Ndr1\(^{T346}\)/SGK1, as well as Akt\(^{T308}\), a PDK1 phosphorylation site that is strongly correlated with Akt kinase activity (Janku et al., 2018; Laplante and Sabatini, 2012).

Inhibition of Rictor/mTORC2-Dependent Akt Signaling Promotes SHH-MB Formation via Prolonging GCP Proliferation

We compared the gene expression profiles of the p53\(^{\Delta S/\Delta S}\)-mutant-driven MBs with those of normal cerebellum; purified granule cell precursors (GCPs, the cells-of-origin of SHH-MBs); and mouse MBs with characteristics of SHH, WNT, and group 3 subgroups (Northcott et al., 2012). Our results showed that the gene expression profile of p53\(^{\Delta S/\Delta S}\)-mutant-driven MBs was strongly associated with SHH-MBs and similar to GCPs, but not the group 3 and WNT MBs or normal cerebellar tissues (Figures 4A and 4B). Furthermore, all 22 p53\(^{\Delta S/\Delta S}\)-mutant-driven MBs, irrespective of Rictor genotype status, expressed high levels of Shh-specific genes, including Glil, Atoh1, Boc, and Sfrp1, which were not expressed in p53\(^{\Delta S/\Delta S}\)-mutant-driven malignant gliomas, the group 3 and WNT MBs, or normal cerebellar tissues (Figures S4A–S4C). qPCR analysis further confirmed that the Shh targets, including Glil, Gl2, N-Myc, and Atoh1, were highly expressed in anaplastic or classic pathology with high cellular density, nuclear molding and Rosette structures, robust p53\(^{\Delta S/\Delta S}\)-expression, and occasional neuronal (synaptophysin) and glial (GFAP) differentiation as seen in human MBs (Figure 3B) (Louis et al., 2016). These p53\(^{\Delta S/\Delta S}\)-mutant-driven MBs exhibited robust Pax6 (a granule cell lineage-specific marker in the cerebellum) expression with minimal levels of Olig2. Conversely, p53\(^{\Delta S/\Delta S}\)-mutant-driven malignant gliomas expressed high levels of Olig2 with minimal expression of Pax6 (Figures 3C–3E). This opposite expression pattern of Pax6 and Olig2 reliably distinguished MBs from malignant gliomas, even when both types of malignant brain tumors were observed in the cerebellum (Figure 3C) or in the different regions of the same brain (Figure 3D).

We found that p53\(^{\Delta S/\Delta S}\)-mutant-driven MBs consistently developed more rapidly than malignant gliomas, arguing against the possibility that the increased MB incidence by Rictor deletion results from extended lifespan as a consequence of inhibiting malignant gliomas (Figure S3B). Moreover, loss of one or two alleles of Rictor on the p53\(^{\Delta S/\Delta S}\)-Pten\(^{-}\)A double mutant background also increased the MB incidence from 17% to 48% and 79%, respectively (Figures S3D–S3G). These observations demonstrate that Rictor deletion, not potential differences in malignant glioma formation or genetic background, leads to a dramatic increase in SHH-MB incidence in both p53\(^{\Delta S/\Delta S}\)- and p53\(^{\Delta S/\Delta S}\)-Pten\(^{-}\)A mice.

Inhibition of Rictor/mTORC2-Dependent Akt Signaling Promotes SHH-MB Formation via Prolonging GCP Proliferation

Despite a robust inhibition of malignant gliomas and prolonged survival by Rictor deletion, a subset of the p53\(^{\Delta S/\Delta S}\)-Rictor\(^{-}\)A mice developed malignant brain tumors at a rate that matched the p53\(^{\Delta S/\Delta S}\)-Rictor\(^{-}\)A mice with the shortest tumor latency (Figure 2A). Almost all of the p53\(^{\Delta S/\Delta S}\)-Rictor\(^{-}\)A mice in this subset developed MBs in the hindbrain, particularly in the cerebellum (Figure 3A). All of the p53\(^{\Delta S/\Delta S}\)-mutant-driven MBs, including p53\(^{\Delta S/\Delta S}\)-Rictor\(^{-}\)A MBs, were characterized as large cell/
Figure 3. Rictor Deletion Promotes p53-Mutant-Driven Medulloblastoma Formation
(A) Scatterplot representation of malignant gliomas and MBs along with their corresponding survival rates in three GEM models.
(B) Histopathological features of the p53D5–6/D5–6 RictorD/Δ MBs. H&E staining shows the dense tumor (i) with carrot-shaped nuclei, apoptotic cells, and nuclear moldings (ii). Tumors were immunoreactive to p53 (iii) and synaptophysin (iv) antibodies. Tumor areas with GFAP+ (v) and GFAP+ (vi) are shown. Insets are higher magnification images.
(D) Pax6 and Olig2 staining in adjacent sections of a p53D5–6/D5–6 RictorD/Δ brain with a malignant glioma in the forebrain and an MB in the cerebellum.
(E) Western blot analysis of MBs from different GEM models. WT cerebellar tissue (CTR) and two malignant glioma samples (last two lanes) are included. SHH-MB-related markers are framed with a red dashed-line box.
(F) Immunohistochemical analysis of Atoh1 expression in MBs and malignant glioma located in the cerebellum.
Scale bars: 50 μm (B), 1 mm (C and D), and 250 μm (F).
See also Figure S3.
p53<sup>Δ5–6</sup>-mutant-driven MBs at comparable levels to the Ptch1 mutant-driven SHH-MBs (Figure 4C). These results demonstrate that Rictor/mTORC2 loss significantly increases the incidence of SHH-MBs on the p53<sup>Δ5–6</sup>-mutant background.

Rictor/mTORC2 loss does not significantly alter the latency or type of MBs on the p53<sup>Δ5–6</sup>-mutant background (Figure 3A). Thus, we hypothesized that the increased incidence of SHH-MBs on p53<sup>Δ5–6</sup>-/C0 mice results from the growth-promoting effects of GCPs, which constitute the external granular layer (EGL), a structure only transiently present in the developing cerebellum (Northcott et al., 2012). At postnatal day 16 (P16), both Pax6<sup>+</sup> and proliferating Pax6<sup>+</sup>BrdU<sup>+</sup> GCPs were readily identified in each folium of Rictor-deficient cerebella (regardless of p53 mutational status), whereas almost no GCPs were present in most folia of control cerebella, accompanied by the disappearance of the EGL (Figures 4D–4F). Overall, the EGL of Rictor-deficient cerebella exhibited a 3-fold and 2-fold of increase in the cellular density and total number of proliferating GCPs, respectively (Figures 4G, S4D, and S4E).

To determine the cellular mechanism by which Rictor deletion promotes sustained proliferation of GCPs, we performed a BrdU pulse-chase assay to investigate cell-cycle exit of GCPs in Rictor-deficient versus Rictor-proficient cerebella from P15 to P17. Consistent with the observations at P16, only a small number of BrdU<sup>+</sup> cells labeled at P16 were still detected at P17 in most of the control folia, most of which exited the cell cycle and migrated out of the EGL into the molecular layer (ML) or the internal granular layer (IGL) (Figures 4H and 4I). In contrast, the number of P15-labeled BrdU<sup>+</sup> cells was dramatically increased in P17 Rictor-deficient cerebella, which was mainly caused by the cells sustained in the EGL, including proliferating BrdU<sup>+</sup>Ki67<sup>+</sup> GCPs (Figures 4H, 4I, and S4F). When cerebellar development was complete at P22, Rictor-deficient cerebella exhibited ectopic accumulation of Pax6<sup>+</sup> cells in the "persistent" EGL (Figures S4G–S4J). More important, abnormally proliferating Pax6<sup>+</sup> GCPs were observed only in Rictor-deficient cerebella, particularly in folium 10b (Figures S4K and S4L). Together, these results are most consistent with a model wherein Rictor deletion delays timely differentiation of a subset of GCPs, prolonging their proliferation in the EGL.

**Pharmacological Inhibition of Akt Signaling Delays GCP Differentiation via Stabilizing Atoh1 Protein**

We investigated the molecular mechanism by which Rictor/mTORC2 loss leads to the delay in timely differentiation of GCPs during cerebellar development. First, we determined Rictor/mTORC2 activity during GCP development using the expression of pAkt<sup>S473</sup>. At the peak of migration of differentiating GCPs in P8 cerebella, almost no pAkt<sup>S473</sup> activity was observed in the EGL, while robust pAkt<sup>S473</sup> expression was found in the ML, and many differentiated neurons were found in the IGL (Figure 5A). Despite high levels of pAkt<sup>S473</sup> expressed in cell bodies and fibers of GFAP<sup>+</sup> Bergmann glial cells, a subset of migrating GCPs with high pAkt<sup>S473</sup> expression was identified in the ML (Figures 5A and S5A). When pAkt<sup>S473</sup> expression became restricted to cell bodies of Bergmann glial cells at P11, a subset of migrating GCPs with high levels of pAkt<sup>S473</sup> was readily identified in the ML (Figure 5B). More important, differentiated granule neurons in the IGL were the only cells with detectable pAkt<sup>S473</sup> expression in the adult cerebellum (Figure S5B). These results demonstrate that high levels of mTORC2/Akt activity are associated with differentiated cells in the granule cell lineage, including a subset of migrating and differentiating GCPs in the ML, and granule neurons in the IGL, but not in undifferentiated GCPs in the EGL.

Second, we sought to determine whether mTORC2-dependent Akt signaling is required for GCP differentiation. We therefore treated WT mice from P8 to P16 with BKM120, one of the most extensively tested pan-PDK/AKT inhibitors in clinical trials (Janku et al., 2018). BKM120 treatment led to a reduction in the weight of the brain, mimicking the postnatal phenotypes observed in Rictor-deficient mice (Figures S5C–S5E and S5F–S5H). BKM120 treatment caused an increased number of proliferating GCPs in the EGL of multiple folia, thus recapitulating abnormally sustained proliferation of Rictor-deficient GCPs (Figures S5C–S5E, S5I, and S5J). Similar to Rictor-deficient cerebella, an abnormal accumulation of GCPs was observed in the EGL of multiple folia of the BKM120-treated cerebella (arrowheads in Figures S5F, S5K, and S5L). BKM120 treatment increased the number of GCPs with expression of Atoh1, a transcription factor that is exclusively expressed in proliferating GCPs in the outer folia of the cerebellum (Northcott et al., 2012). At postnatal day 16 (P16), both Pax6<sup>+</sup> and proliferating Pax6<sup>+</sup>BrdU<sup>+</sup> GCPs were readily identified in each folium of Rictor-deficient cerebella (regardless of p53 mutational status), whereas almost no GCPs were present in most folia of control cerebella, accompanied by the disappearance of the EGL (Figures 4D–4F). Overall, the EGL of Rictor-deficient cerebella exhibited a 3-fold and 2-fold of increase in the cellular density and total number of proliferating GCPs, respectively (Figures 4G, S4D, and S4E).

**Figure 4. Rictor Deletion Promotes SHH-MB Formation by Prolonging the Proliferation of Granule Cell Precursors**

(A and B) Microarray analysis of genome-wide expression profiles of the p53-mutant-driven MBs in comparison with normal cerebellum and previously published GEM models of WNT, SHH, and group 3 MBs. An area containing the genes specifically upregulated in the SHH-MBs and GCPs is highlighted with the horizontal white box (A). The genes in this area are listed in (B) and the important ones are highlighted in yellow.

(C) qPCR experiments were performed using cDNAs from p53<sup>Δ5–6</sup>-driven MBs in comparison with the Ptch1<sup>−/−</sup> models. Two malignant glioma samples and one P13 normal cerebellar tissue were used as negative controls.

(D–G) Control and mutant mice at P16 were injected with BrdU and analyzed 2 hr later. The overall cerebellar structure along with the Pax6<sup>+</sup> cells and BrdU<sup>+</sup> proliferating cells were examined. Each folium (“F”) is labeled with Roman numerals (D). White frames indicate three areas (F–5/6, F–9/10a, and F–10b) that were subjected to further analysis. Two types of Rictor mutant mice are highlighted by red dashed-line boxes. Higher magnification of F–9/10a regions in (D) and corresponding H&E staining is shown (E). Pax6<sup>+</sup> cells and proliferating BrdU<sup>+</sup>BrdU<sup>+</sup> cells in the EGL-associated areas were quantified in three folia of P16 control and mutant cerebella (F). The total number of BrdU<sup>+</sup> proliferating cells per unit area (mm<sup>2</sup>) was calculated for control and mutant cerebella individually (G).

(H) Cell-cycle analysis was performed by injecting the mice with BrdU once at P15 and analyzing at P17. Two types of Rictor mutant mice are highlighted by red dashed-line boxes. (H) The cells proliferating at P15 were labeled with BrdU upon injection. Those subsequently exiting the cell cycle at P17 were labeled BrdU<sup>+</sup>Ki67<sup>+</sup> (green), and those remained or re-entered cell cycle were labeled BrdU<sup>+</sup>Ki67<sup>+</sup> (yellow). Higher magnification view of the EGL cells in F–5/6, F–9/10a, and F–10b are shown. (I) The number of BrdU<sup>+</sup> cells in EGL, ML, and IGL are quantified. The distribution of each type of BrdU<sup>+</sup> cells is shown with bar graphs. The p values for the comparisons of BrdU<sup>+</sup>Ki67<sup>+</sup> cells in EGL (yellow bars) are shown. Additional comparisons are listed in Figure S4F.

All of the quantification data are presented as means ± SEMs. Unpaired Student’s t test was used to compare the groups statistically. Scale bars: 1 mm (D), 100 μm (E), and 250 μm (H). EGL, external granular layer; IGL, internal granular layer; ML, molecular layer.

See also Figure S4.
Given that Atoh1 is required for maintaining an undifferentiated state of proliferating GCPs (Ayrault et al., 2010), these results raise the possibility that genetic and pharmacological inhibition of Akt signaling leads to increased Atoh1 expression, delaying timely differentiation of GCPs and prolonging their proliferation.

Third, we established and screened early-passage p53^{−/−}Rictor^{−/−}mutant-driven MB cell lines that maintained high levels of Atoh1 expression in their primary tumors, allowing us to investigate the regulation of endogenous Atoh1 protein (Figures 3E and 3F). In contrast to DMSO-treated cells, BKM120 treatment inhibited Akt activation and promoted accumulation of Atoh1 protein in a dose-dependent manner. At a low dose of 0.1 μM, BKM120 greatly inhibited Akt activation without inducing apoptosis (Figure 5 I). Of note, a higher concentration at 0.5 μM, despite further inhibiting Akt activity, induced apoptosis at later time points. More important, BKM120-mediated accumulation of Atoh1 protein was observed in a time-dependent manner.

EGL (Figures 5G and 5H). Given that Atoh1 is required for maintaining an undifferentiated state of proliferating GCPs (Ayrault et al., 2010), these results raise the possibility that genetic and pharmacological inhibition of Akt signaling leads to increased Atoh1 expression, delaying timely differentiation of GCPs and prolonging their proliferation.

Third, we established and screened early-passage p53^{−/−}Rictor^{−/−}mutant-driven MB cell lines that maintained high levels of Atoh1 expression of their primary tumors, allowing us to investi-
p53-Mutant-Driven SHH-MBs Share Critical Features of
TP53 Mutant SHH-MBs in Humans

The persistent proliferation of Rictor-deficient GCPs exclusively observed on the p53^{35-6}/p53^{35-6} background suggests a p53-dependent cellular response or responses that drive the cell-cycle exit of abnormally proliferating Rictor-deficient Pax6^+ GCPs at the late stages of cerebellar development (Figures S6A–S6C). This tumor-suppressive response explains that Rictor/mTORC2 loss did not induce SHH-MBs on the p53^{+/+} or p53^{+/+} background. The activation of p53-mediated responses in Rictor-deficient GCPs was consistent with the observation that p53^{35-6} cells were readily identified in multiple folia of the p53^{35-6}/p53^{35-6}Rictor^{+/+} but not p53^{35-6}/p53^{35-6} cerebella at P22 (Figures 6A and 6B). Many p53^{35-6}/p53^{35-6}Rictor^{+/+} cerebella (4/7) but not p53^{35-6}/p53^{35-6} cerebella (n = 6) contained clusters of p53^{35-6} cells at P60, some of which were proliferating, reminiscent of MB precursor cells (Figures 6C and S6D). It is important to note that the percentage of proliferating cells expressing p53^{35-6} (BrdU^+ p53^{+/+}/BrdU^+) almost reached 80%–100% at P60 compared to 10%–20% in GCPs at P16, suggesting clonal selection from p53^{35-6} GCPs during postnatal development to MB precursor cells in young adult cerebella (Figures 6C and S6A–S6C). Thus, Rictor/mTORC2 loss expands and prolongs the GCP population that is susceptible to p53^{35-6}-mutant-driven SHH-MB formation during postnatal cerebellar development.

Although virtually all p53-deficient SHH-MBs of previously published mouse models harbor biallelic inactivation of Ptc1 (Frappart et al., 2009), TP53 mutant SHH-MBs in humans infrequently carry PTC1 mutations and have at least one normal PTC1 allele (Kool et al., 2014; Northcott et al., 2012). We performed qPCR, targeted deep sequencing of the Ptc1 gene (~300x), and low-coverage whole-genome sequencing (~10x), demonstrating that a significant number of p53^{35-6}-mutant-driven SHH-MBs, regardless of Rictor status, retained at least one WT allele of Ptc1 (Figure 6D, marked by *, and S6E). In particular, ~70% of Rictor-deficient SHH-MBs exhibited either WT or heterozygous Ptc1, with a high frequency of amplification of N-Myc and/or Gli2, the critical features of human TP53 mutant SHH-MBs (Figures 6E, 6F, and S6F). In contrast, almost all Ptc1 mutant-driven MBs analyzed in this study (>90%, n = 32) harbored biallelic Ptc1 inactivation (via loss of Ptc1 WT allele) (Figures 6D and S6E). Moreover, p53^{35-6}-mutant-driven SHH-MBs also exhibited other critical genomic features of human TP53 mutant SHH-MBs, including heterozygous loss of chr10q/PTEN and chromosomal abnormalities such as tetraploidy, harboring four times the haploid number of chromosomes (Figures S6G–S6M, S7A, and S7B) (Kool et al., 2014). These results demonstrate that Rictor deletion promotes p53^{35-6}-mutant-driven SHH-MBs, which recapitulate the critical histopathological, molecular, genetic, and genomic features of TP53 mutant SHH-MBs in humans. In summary, these observations demonstrate that Rictor deletion promotes the rapid generation of p53^{35-6} MB precursor cells from GCPs in the EGL during late stages of cerebellar development, while delaying the emergence of p53^{35-6} glioma precursor cells from the SVZ stem cell niche of the adult brain (Figure S7C).

Impact of RICTOR Expression in Pediatric SHH-MBs and Adult GBMs in Humans

Despite high levels of similarity between mouse p53^{35-6}-mutant SHH-MBs and human TP53 mutant SHH-MBs, no homozygous deletion of RICTOR was identified in human SHH-MBs (Kool et al., 2014). We therefore used a bioinformatics approach to divide pediatric SHH-MBs into “RICTOR-high” and “RICTOR-low” groups based on mRNA expression data (see STAR Methods). The SHH-MBs within the RICTOR-low group were associated with poor survival among pediatric SHH-MBs (Figures 7A and 7B). TP53 mutant SHH-MBs are one of the two MB subgroups with the worst survival rates and are responsible for the majority of the mortality associated with SHH-MBs (Kool et al., 2014; Northcott et al., 2012). The majority of TP53 mutant SHH-MBs (~65%) were consistently observed in the group, with the lowest RICTOR expression found among SHH-MBs (Figures 7A and 7B). Thus, the poor survival of the RICTOR-low group is at least partially contributed to by an enrichment of TP53 mutant SHH-MBs. Among TP53-WT SHH-MBs, more pediatric patients with lower levels of RICTOR expression died during the follow-up studies (Figures 7C and 7D). These results suggest that low levels of RICTOR expression may negatively affect patient survival independent of its association with TP53 mutations, although a large number of patients with SHH-MBs are needed to validate this observation.

Given that the mTORC2-dependent AKT signaling is the major downstream effect of the PI3K/PTEN pathway, we further determined the frequency of mutational events in the PI3K/AKT pathway in SHH-MBs and compared them to adult primary GBMs, most of which exhibit genetic alterations in the PI3K/AKT pathway (Brennan et al., 2013). Approximately 32% of infant, 39% of childhood, and 16% of adult SHH-MBs exhibited the
Figure 6. p53-Mutant-Driven MBs Share Critical Features of TP53 Mutant SHH-MBs in Humans
(B) The total number of p53Δ5–6+ cells in three different folia from P22 WT and mutant mice is shown.
(D) SHH pathway alterations in SHH-MBs from different GEM models.
(E) Analysis of CNAs in N-Myc and Gli2 genes in a bigger pool of MB samples. Copy-number ratios ≥1.25 were considered low-level amplifications/gains (orange area), ratios >2 were considered high-level amplifications (light red area).
(F) Amplified chromosomal regions containing N-Myc and Gli2 genes (red) detected by low-coverage whole-genome sequencing (lcWGS). This parameter is shown as a ratio of tumor versus control tissue. Baseline is shown with a red line across the plots.

Scale bars: 50 μm (A and C). EGL, external granular layer; IGL, internal granular layer; ML, molecular layer. See also Figures S6 and S7.
Figure 7. RICTOR Expression Is Correlated with Opposite Clinical Outcomes in Adult GBMs and Pediatric SHH-MBs

(A–D) Scatterplot distribution of RICTOR gene expression among all pediatric SHH-MBs (A) or pediatric SHH-MBs with WT TP53 only (C). Patients who succumbed to the disease are indicated with red dots, while the survivors at the time of analysis are shown with green dots. The survival analysis for both groups is shown in (B) and (D). Tumors with detected TP53 mutations are indicated with asterisks in (B).

(E) Distribution of TP53, PTEN, and PIK3CA gene mutations and chr10q loss in SHH-MBs among the three age subgroups.

(F) The frequencies of 10q loss, biallelic PTEN inactivation, and pAKT positivity (* derived from two previous studies) are compared between adult primary GBMs and SHH-MBs.
loss of one copy of chr10q/PTEN (heterozygous loss) (Figures 7E and 7F). In contrast, nearly all IDH-WT GBMs (97% of 221 cases in The Cancer Genome Atlas [TCGA] database) exhibited chr10q/PTEN loss (Figure 7F) (Brennan et al., 2013). More important, biallelic inactivation of PTEN caused by homozygous deletions or additional loss-of-function mutations in the second allele was observed in 41% of adult primary GBMs, which rarely occurred in infant (6%) and adult SHH-MBs (4%) and none in childhood SHH-MBs (0%), the age group that harbors the most TP53 mutations (Figures 7F and 7G). Genetic alterations in the PIK3CA were also rare in pediatric SHH-MBs (infant, 6% and childhood, 0%) (Figure 7E). Together, high versus low frequency of genomic and molecular alterations in the PI3K/AKT signaling pathway in human adult primary GBMs versus pediatric SHH-MBs are consistent with the opposing tumor-promoting versus tumor-suppressing effects of Rictor/mTORC2-dependent Akt signaling observed in our mouse studies. In support, adult IDH-WT/non-G-CIMP GBMs with high levels of RICTOR mRNA expression were associated with poor survival, particularly for the patients surviving >7 months (Figures 7H–7J). RICTOR is the only component of mTORC2 or mTORC1 whose mRNA expression level has an opposite relation to survival of pediatric SHH-MBs and adult GBMs (Figure S8).

**DISCUSSION**

The unique aspect of the conditional p53<sup>35–6</sup> brain tumor model is that the driving p53<sup>35–6</sup> mutation itself does not directly provide growth advantage but instead allows spontaneous accumulation of oncogenic alterations in targeted cells, which in turn drive malignant transformation. Despite the p53<sup>35–6</sup> mutation being conditionally targeted toward embryonic neural stem cells and mature astrocytes, no tumor in the brain was observed until late adulthood (6–12 months) (Figure 5A) (Wang et al., 2009, 2012). The cell- or cells-of-origin of these p53<sup>35–6</sup>-mutant-driven brain tumors must be the cells with self-renewing potentials (e.g., neural stem and progenitor cells) that can undergo multiple cell divisions, allowing spontaneous accumulation of oncogenic alterations sufficient for malignant transformation (Ihrie and Alvarez-Buylla, 2011; Northcott et al., 2012). Thus, the conditional p53<sup>35–6</sup> brain tumor model provides an experimental system with which to discover and validate oncogenic drivers that accumulate in neural stem and progenitor cell populations, which would directly confer growth advantage during the initiation and progression of p53<sup>35–6</sup>-mutant-driven malignant gliomas and SHH-MBs.

The vast majority of p53<sup>35–6</sup>-mutant mice acquire chr19/Pten loss during malignant glioma formation. The presence of additional Pten<sup>1/-</sup> mutation on the p53<sup>35–6</sup>-mutant background circumvents chr19/Pten loss, which is also absent in GFAP-creER (estrogen receptor)-driven p53/Pten-double or p53/Pten/Rb-triple mutant models (Chow et al., 2011). These observations suggest that the major target of chr19 loss is the Pten tumor-suppressor gene, which consequently activates the PI3K/Akt signaling pathway in this glioma model. Rictor/mTORC2 loss consistently inhibits Akt signaling, thereby reducing the incidence and delaying the formation of malignant gliomas and GBMs in both p53<sup>35–6</sup>-mutant and p53<sup>35–6</sup>/Pten<sup>1/-</sup>-double mutant-driven models. Recent studies using human GBM cells have demonstrated that RICTOR/mTORC2 integrates intracellular growth factor receptor signaling with extracellular nutrient availability, reprogramming cancer metabolism and causing drug resistance of PI3K/AKT/mTOR inhibitors (Masui et al., 2013, 2015; Wu et al., 2014). The availability of GEM Rictor-proficient and Rictor-deficient malignant gliomas and GBMs provides an in vivo experimental system with an immunocompetent environment in which to investigate Akt-dependent and Akt-independent mechanisms of mTORC2 in reprogramming GBM metabolism. Furthermore, preclinical studies will be performed to target metabolic vulnerability caused by mTORC2 inhibition in these GEM models. Despite the potent inhibition of mTORC1, mTORC2, and Akt signaling pathways, it should be noted that the emergence of Rictor-deficient gliomas highlights the utility of this glioma model to investigate therapeutic resistance to PI3K/AKT/mTOR inhibitors.

We have identified a novel tumor-suppressive function of Rictor/mTORC2 in the pathogenesis of p53<sup>35–6</sup>-mutant-driven SHH-MBs. It has been well documented that neural stem cells in the SVZ stem cell niche remain undifferentiated throughout the lifespan, providing the opportunity for p53<sup>35–6</sup>-mutant cells to accumulate oncogenic alterations that are sufficient for malignant glioma/GBM formation (Ihrie and Alvarez-Buylla, 2011; Wang et al., 2009; Zhu et al., 2005). However, GCPs are a transient precursor population during cerebellar development, which must accumulate oncogenic alterations during a limited developmental window to generate MB precursors (Northcott et al., 2012). Mechanistically, Rictor deletion causes a delay in timely differentiation of a subset of GCPs, whose differentiation is associated with the activation of mTORC2/Akt signaling. Consequently, these Rictor-deficient GCPs abnormally continue to proliferate in the persistent EGL. The sustained proliferating GCPs therefore increase the population size for tumor-susceptible cells to accumulate oncogenic alterations (e.g., Gli2 and or N-Myc amplification), leading to increased SHH-MB penetrance on the p53<sup>35–6</sup>-mutant background. These observations suggest that the shift of the tumor spectrum from malignant gliomas to SHH-MBs results from the opposing role of Rictor/mTORC2 in neural stem cells in the adult SVZ versus GCPs in the EGL in the postnatal developing cerebellum (Figure S7C).
Pharmacological inhibition of the PI3K/Akt signaling pathway during postnatal cerebellar development blocks GCP differentiation and increases the sustained proliferating GCP population during postnatal cerebellar development (Dimitrova and Arcaro, 2015). Thus, the effects of this PI3K/AKT inhibitor treatment partially mimic the delayed differentiation and sustained proliferation of GCPs observed in Rictor-deficient cerebella. Along with the observation that highly phosphorylated AktSer473 is associated with the differentiation of GCPs, these results demonstrate a critical role for Rictor/mTORC2-dependent Akt signaling in promoting differentiation of a subset of GCPs and suppressing SHH-MB formation. Increased numbers of GCPs with Atoh1 expression observed in BKM120-treated cerebella suggest a mechanistic basis of the negative role of Rictor/mTORC2/Akt signaling in GCP proliferation. We provide direct evidence that Akt inhibition promotes the accumulation of Atoh1 protein, possibly via blocking CRL-mediated protein degradation. These results provide a molecular mechanism for a recent clinical observation that no or low levels of Akt or mTORC1 activity are detected in most pediatric SHH-MBs (Kool et al., 2014). We also observed low Akt activation in 5 human MB-derived cell lines (3 SHH-MB lines and 2 group 3/4 lines), which are more resistant to a PI3K/AKT inhibitor compared to GBM cell lines (S.A., unpublished data). It will be important to validate the tumor-suppressive functions of mTORC2/AKT signaling in patient-derived cell lines and xenograft models of MBs. Thus, our study suggests that caution should be taken in the design of clinical trials using PI3K/AKT/mTOR inhibitors to treat brain tumors in children (Dimitrova and Arcaro, 2015; Janku et al., 2018).

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **CONTACT FOR REAGENT AND RESOURCE SHARING**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
- **METHODS DETAILS**
  - Genotyping and PCR
  - Tissue Preparation, Histopathology and Tumor Diagnosis
  - Immunohistochemistry and Immunofluorescence
  - BrdU Assay for the Analyses of Proliferation and Differentiation
  - BKM120 Treatment Study
  - Identification of p53^{35-6}, positive Early Tumor Precursors for Malignant Gioma and Medulloblastoma
  - Western Blotting Analysis
  - Tumor-Sphere Cell Culture and Chromosome Assay
  - RT-PCR for Copy Number Analyses
  - RT-PCR for Gene Expression Analyses
  - Protein half-life analysis of Atoh1
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
- **DATA AND SOFTWARE AVAILABILITY**

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes eight figures and two tables and can be found with this article online at https://doi.org/10.1016/j.celrep.2018.06.050.

**ACKNOWLEDGMENTS**

We thank T. Burns, E. Kim, and E. Li for technical assistance; members of the Zhu lab for support; Drs. E. Lee, A. Messing, and T. Mak for providing p53^{35-6}, hGFAP-cre, and Pten^{35} mice, respectively; J. Johnson for the Atoh1 antibody; Dr. Y. Sun for reagents; and Dr. Bornhorst and E. Fetzner for critically reading the manuscript. This work is supported by grants from the NIH (Z01 CA058578-10A1 and R01 NS053900) and the Cellular & Molecular Biology-Coleman Fellowship, University of Michigan.

**AUTHOR CONTRIBUTIONS**

S.A., Y.L., and Y.Z. conceived and designed the study. S.A., Y.L., D.M.T., C.L., Y.W., G.T., and V.G. performed the experiments. S.A., Y.L., and Y.Z. analyzed the results. S.Z. and R.G.W.V. conducted the bioinformatics analysis related to gliomas. M.K., S.G., S. Stark, and S.M.P. performed the genome-wide analysis of MBs. S.C.-P. performed the pathological diagnoses. Y.S. and J.F.G. performed the array comparative genomic hybridization (aCGH) study of gliomas. T.I. and K.-L.G. assisted with supervision and resources. Y.Z. and S.A. acquired the funding and wrote the manuscript with contributions from all of the authors.

**DECLARATION OF INTERESTS**

The authors declare no competing interests.

Received: July 12, 2017
Revised: May 7, 2018
Accepted: June 12, 2018
Published: July 10, 2018

**REFERENCES**


### Key Resources Table

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibodies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rabbit anti-p53</td>
<td>Leica</td>
<td>P53-CM5P-L</td>
</tr>
<tr>
<td>Rabbit anti-Olig2</td>
<td>Millipore</td>
<td>AB9610</td>
</tr>
<tr>
<td>Rabbit anti-GFAP</td>
<td>Dako</td>
<td>Z0334</td>
</tr>
<tr>
<td>Rabbit anti-Synaptophysin</td>
<td>Covance</td>
<td>MMS-618R</td>
</tr>
<tr>
<td>Rabbit anti-Pax6</td>
<td>Covance</td>
<td>PRB-278p</td>
</tr>
<tr>
<td>Rabbit anti-Ki67</td>
<td>Abcam</td>
<td>ab15580</td>
</tr>
<tr>
<td>Rabbit anti-pAktS473</td>
<td>Cell Signaling</td>
<td>4060L</td>
</tr>
<tr>
<td>Rabbit anti-Atoh1</td>
<td>Dr. Jane Johnson from UT Southwestern</td>
<td>N/A</td>
</tr>
<tr>
<td>Mouse anti-Atoh1</td>
<td>Abcam</td>
<td>ab27667</td>
</tr>
<tr>
<td>Mouse anti-Atoh1</td>
<td>Developmental Studies Hybridoma Bank</td>
<td>N/A</td>
</tr>
<tr>
<td>Rat anti-BrdU</td>
<td>Abcam</td>
<td>ab6326</td>
</tr>
<tr>
<td>Mouse anti-Ascl1/Mash1</td>
<td>BD PharMingen</td>
<td>556604</td>
</tr>
<tr>
<td>Mouse anti-Nestin</td>
<td>Millipore</td>
<td>MAB353</td>
</tr>
<tr>
<td>Goat anti-Sox2</td>
<td>Santa Cruz Biotech</td>
<td>sc-17320</td>
</tr>
<tr>
<td>Mouse anti-Calbindin</td>
<td>Sigma-Aldrich</td>
<td>C9848</td>
</tr>
<tr>
<td>Mouse anti-NeuN</td>
<td>Millipore</td>
<td>MAB377</td>
</tr>
<tr>
<td>Alexa Fluor 488</td>
<td>Invitrogen, Life Technologies</td>
<td>A11004; A11034</td>
</tr>
<tr>
<td>Alexa Fluor 555</td>
<td>Invitrogen, Life Technologies</td>
<td>A21429; A21424</td>
</tr>
<tr>
<td>Alexa Fluor 647</td>
<td>Invitrogen, Life Technologies</td>
<td>A31571; A21236; A21247; A21245</td>
</tr>
<tr>
<td>Alexa Fluor 555–conjugated streptavidin</td>
<td>Thermo Fisher Scientific</td>
<td>S-32355</td>
</tr>
<tr>
<td>Rabbit anti-pAktT308</td>
<td>Cell Signaling</td>
<td>2965S</td>
</tr>
<tr>
<td>Rabbit anti-Akt</td>
<td>Cell Signaling</td>
<td>9272S</td>
</tr>
<tr>
<td>Rabbit anti-pNDRG1T346</td>
<td>Cell Signaling</td>
<td>5482S</td>
</tr>
<tr>
<td>Rabbit anti-Pten</td>
<td>Cell Signaling</td>
<td>9559S</td>
</tr>
<tr>
<td>Rabbit anti-Rictor</td>
<td>Dr. D. Fingar from University of Michigan</td>
<td>N/A</td>
</tr>
<tr>
<td>Rabbit anti-mTOR</td>
<td>Cell Signaling</td>
<td>2983S</td>
</tr>
<tr>
<td>Mouse anti-β-Actin</td>
<td>Sigma-Aldrich</td>
<td>A5316</td>
</tr>
<tr>
<td>Rabbit anti-pS6K^{T389}</td>
<td>Cell Signaling</td>
<td>9234S</td>
</tr>
<tr>
<td>Rabbit anti-p4E-BPI^{T37/46}</td>
<td>Cell Signaling</td>
<td>9459S</td>
</tr>
<tr>
<td>Rabbit anti-pTSC2^{T1462}</td>
<td>Cell Signaling</td>
<td>8350S</td>
</tr>
<tr>
<td>Rabbit anti-pS6^{S240/244}</td>
<td>Cell Signaling</td>
<td>5364S</td>
</tr>
<tr>
<td>Rabbit anti-S6</td>
<td>Cell Signaling</td>
<td>2217S</td>
</tr>
<tr>
<td>Rabbit anti-cMyc</td>
<td>Cell Signaling</td>
<td>5605S</td>
</tr>
<tr>
<td>Rabbit anti-pErk1/2^{T202/Ty204}</td>
<td>Cell Signaling</td>
<td>9101S</td>
</tr>
<tr>
<td>Rabbit anti-Erk1/2</td>
<td>Cell Signaling</td>
<td>9102L</td>
</tr>
<tr>
<td>Rabbit anti-pGSK-3β^{S47}</td>
<td>Cell Signaling</td>
<td>5558S</td>
</tr>
<tr>
<td>Mouse anti-P120</td>
<td>BD Biosciences</td>
<td>610040</td>
</tr>
<tr>
<td>Rabbit anti-Gil1</td>
<td>Cell Signaling</td>
<td>2534S</td>
</tr>
<tr>
<td>Rabbit anti-Atoh1</td>
<td>Abcam</td>
<td>ab168374</td>
</tr>
<tr>
<td>Cleaved-Caspase3</td>
<td>Cell Signaling</td>
<td>9661S</td>
</tr>
<tr>
<td>Mouse anti-Cul-1</td>
<td>Santa Cruz</td>
<td>sc-17775</td>
</tr>
</tbody>
</table>

(Continued on next page)
EXPERIMENTAL MODEL AND SUBJECT DETAILS

The mutant mice used in this study had various genotypic configurations: For brain tumor formation, hGFAP-cre; p53<sup>flox/flox</sup>, hGFAP-cre;pS3<sup>flox/flox/Rictor<sup>flox/+</sup> mice were used. A second group of mice as a validation cohort carried additional heterozygous Pten<sup>flox/+</sup> mutation. Brain tumors from a group of Pch<sup>1+/−</sup> mice with the genotype of hGFAP-cre;Ptch<sup>1+/−</sup> and hGFAP-cre;pS3<sup>flox/flox/Ptch<sup>1+/−</sup> were used as SHH-MB controls. For developmental biology studies, we utilized a non-tumorigenic mutant mouse model with the genotype of hGFAP-cre;pS3<sup>flox/+</sup>Rictor<sup>flox/flox</sup>. The control group was a collection of hGFAP-cre<sup>negative</sup> mice that were phenotypically indistinguishable and completely healthy. Age and littermate-matched control and mutant mice were used for the developmental analyses to minimize the impact of modifier genes. Brain tumor mice were either littermates or close relatives collected over approximately 9 years. All mice except for the original Ptch<sup>1+/−</sup> allele that contained the FVB background were maintained in the mixed backgrounds of C57Bl/6 and 129S1/SvJ. The phenotypes of both malignant gliomas/GBMs and SHH-MBs were similarly observed in male and female mice. Consequently, similar numbers of mice with both genders
were used for the experiments. Mice were cared for according to the guidelines that were approved by the Animal Care and Use Committees of the University of Michigan at Ann Arbor and Children’s National Medical Center, Washington, DC.

METHODS DETAILS

Genotyping and PCR
Taq 2X MeanGreen Master Mix (Empirical Bioscience) was used in PCR experiments along with the following primer sets for tail and tumor tissue genotyping. See primer information in Table S2.

Tissue Preparation, Histopathology and Tumor Diagnosis
Approximately 65%–70% of the mice were sacrificed due to observable neurological symptoms including enlarged head, tremor, seizure, ataxia, or lack of balance indicating the presence of an end-stage brain tumor. One set of these mice were perfused using 4% paraformaldehyde (PFA), brains were collected and kept in 4% PFA for at least one day. The second set of mice were sacrificed using cervical dislocation procedure after anesthesia with 3.5% Tribromoethanol (Avertin). The brains were collected at 4°C, rinsed in 4°C PBS and cut sagittally along the midline. One half of the brain was kept in 4% PFA while the other half was used for frozen tissue collection, snap freezing in liquid nitrogen, and cell culture preparation. Processed and paraffin embedded brain samples were sectioned sagittally at 5 μm and collected on Superfrost Plus microscope slides (Fisher Scientific). Hematoxylin and eosin (H&E) staining was performed approximately every 10 slides and adjacent sections were subjected to immunohistochemical analysis using the antibodies for p53, Olig2, GFAP, Synaptophysin and Pax6. Samples were analyzed under a light microscope by two investigators staining was performed approximately every 10 slides and adjacent sections were subjected to immunohistochemical analysis using the antibodies for p53, Olig2, GFAP, Synaptophysin and Pax6. Samples were analyzed under a light microscope by two investigators (SCP and SA) based upon the World Health Organization (WHO) criteria of the classification of tumors in the CNS (Loui et al., 2016). Diagnosed high-grade malignant gliomas included anaplastic astrocytoma, glioblastoma, anaplastic oligoastrocytoma and anaplastic oligodendroglioma. Final diagnoses were reached as a consensus of H&E staining findings and immunohistochemical analyses. In rare cases where a clear diagnosis was hard to reach, Olig2 and Pax6 immunohistochemistry staining (described below) were taken as conclusive criteria as Olig2 is characteristic of high-grade malignant gliomas whereas Pax6 labels medulloblastomas.

Immunohistochemistry and Immunofluorescence
Adjacent paraffin sections were used in immunohistochemistry and immunofluorescence analyses. Slides were first deparaffinized through a series of Xylene, Ethanol and PBS treatments, boiled in Retrieve-All antigen unmasking system (Covance), permeabilized in 0.3% Triton X-100 (Sigma-Aldrich) and blocked with 5% normal goat serum or normal donkey serum prior to overnight primary antibody incubation at 4°C. The visualization of the primary antibodies in immunohistochemistry was performed with the avidin/biotin-based peroxidase system (Vectastain Elite ABC System, Vector Laboratories), except for pAkt$^{S473}$ and Pten, for which SignalStain Boost IHC Detection Reagent HRP-rabbit (Cell Signaling) was used. The dilutions of the primary antibodies used on paraffin sections in immunohistochemistry study were: p53 (1:500, rabbit, Leica), Olig2 (1:2,000, rabbit, Millipore), GFAP (1:1,000, rabbit, Dako), Synaptophysin (1:200, rabbit, Covance), Pax6 (1:500, rabbit, Covance), Ki67 (1:500, rabbit, Abcam), pAkt$^{S473}$ (1:200, rabbit, Cell Signaling), Pten (1:400, rabbit, Cell Signaling) and Atoh1 (1:500, rabbit, gift from Dr. Jane Johnson from UT Southwestern). Hema-toxylin was used as a counterstain to label cell nuclei. Sections were examined under a light microscope (Olympus BX51 and BX53).

For Atoh1 IHC on paraffin sections, we tested three different Atoh1 antibodies: two mouse antibodies from Abcam (Ab27667) and DSHB (Atoh1 concentrate) and one rabbit antibody (gift from Dr. Jane Johnson from UT Southwestern). Only the rabbit Atoh1 antibody gives the strongest and robust staining on SHH-MBs paraffin sections with small modifications of the IHC protocol mentioned above. For the DAB reaction step, we put the tissue slides on ice to slow down the reaction and reduce some background staining. The freshness of tissue samples has big impact on the Atoh1 staining, with high staining in more fresh samples. We performed Atoh1 IHC on total 46 SHH-MBs including p53$^{15-6/6-15}$-Pten$^{-/-}$ (n = 4); p53$^{15-6/6-15}$-Rictor$^{-/-}$ (n = 17) and p53$^{15-6/6-15}$-Rictor$^{15-13}$ (n = 22). Over 80% of the tumor samples have extensively high level of Atoh1 expression, a signature of SHH MBs.

The visualization of the primary antibodies in immunofluorescence was performed with the use of the Alexa488, Alexa555 and Alexa647 conjugated secondary antibodies (1:400, Invitrogen, Life Technologies). Primary antibodies used for immunofluorescence were: p53 (1:500, rabbit, Leica), BrdU (1:500, rat, Abcam), Olig2 (1:200, rabbit, Millipore), Ki67 (1:500, rabbit, Abcam), Ascl1 (1:100-1:200, mouse, BD Pharmingen), GFAP (1:1,000-1:2,000, rabbit, Dako), Nestin (1:100, mouse, Millipore), Sox2 (1:250, goat, Santa Cruz Biotech), Pax6 (1:500, rabbit, Covance), Calbindin (1:1000, mouse, Sigma) and NeuN (1:500, mouse, Millipore). For pAkt$^{S473}$ (1:300, rabbit, Cell Signaling) staining, biotin-conjugated secondary antibody was used, followed by signal amplification with Alexa555-conjugated streptavidin (Thermo Fisher Scientific, S-32355). DAPI was used as a counterstain to label individual cell nuclei. Sections were examined under a fluorescence microscope (Olympus BX53).

BrdU Assay for the Analyses of Proliferation and Differentiation
For the proliferation assay, mice were injected with 50 μg of BrdU per gram of body weight. Embryonic and newborn mice received one injection, pups and neonatal mice up to 30 days old received two, mice around two months old received three and adult mice older than two months old received five injections, with multiple injections applied at two hour-intervals. All of the mice were perfused with 4% PFA two hours after the final BrdU injection. For the differentiation assay, P15 mice were injected with a 50 μg of BrdU per gram of body weight pulse and perfused with 4% PFA following a 48-hour chase. In both assays, brains were dissected and
processed for either paraffin-embedded or cryostat sections. BrdU immunofluorescence was performed as described previously (Wang et al., 2009).

**BKM120 Treatment Study**

The wild-type pups were injected with 10mg/KG BKM120 (Selleckchem, S2247) or Vehicle (10% Kolliphor EL (Sigma-Aldrich, CS135), 10% PEG400 (Sigma-Aldrich, 202398)) daily from P8 to P16. After the injection at P16, the mice were injected with 50 μg of BrdU per gram of body weight for two times at two hour-intervals. Then the mice were collected as mentioned above.

**Identification of p53<sup>5-6</sup>-positive Early Tumor Precursors for Malignant Glioma and Medulloblastoma**

Early glioma precursors are defined as p53<sup>5-6</sup>-positive cell clusters (> 20 cells per high magnification view) in brain regions (e.g., corpus callosum) outside the SVZ/RMS germinal zone in 4-7 month old p53<sup>5-6/5-6</sup> brains. Early medulloblastoma precursors are defined as p53<sup>5-6</sup>-positive cell clusters (> 10 cells per high magnification view) in the “persistent” EGL in the cerebella of p53<sup>5-6/5-6</sup> (with or without Rictor deletion) at the age of P22 or older. At these time points, there is almost no proliferation in afore-mentioned brain regions in control mice. In p53<sup>5-6/5-6</sup> (with or without Rictor deletion) brains, although not all the p53<sup>5-6</sup>-positive cells in the cluster are BrdU<sup>+</sup>, the majority of BrdU<sup>+</sup> abnormal proliferating cells are p53<sup>5-6</sup>-positive, which provides the basis of using the p53<sup>5-6</sup> marker to label the early tumor precursor cells in the morphologically normal brains.

**Western Blotting Analysis**

Snap-frozen tissue samples from wild-type control brains and tumors were homogenized in Pierce RIPA Buffer (Thermo Fisher Scientific) (10 μL buffer/1 mg tissue), mixed 1:1 with Laemmli Sample Buffer (BioRad) and boiled at 100°C for 8 minutes. Samples were then subjected to SDS-PAGE using the Criterion TGX Precast gels (BioRad) and transferred onto PVDF membranes (Millipore). The membranes were blocked in 5% non-fat milk prepared in TBST and prior to an overnight incubation at 4°C. Next the membranes were washed with TBST and incubated in horseradish peroxidase (HRP)-conjugated secondary antibodies at room temperature for 1 hour. Signal was detected using Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific). The primary antibodies used in this study were as follows: pAkt<sup>S473</sup> (1:1,000, rabbit, Cell Signaling), pAkt<sup>T308</sup> (1:1,000, rabbit, Cell Signaling), Akt (1:1,000, rabbit, Cell Signaling), pNDRG1<sup>T346</sup> (1:1,000, rabbit, Cell Signaling), Pten (1:1,000, rabbit, Cell Signaling), Rictor (1:500, rabbit, gift from Dr. D. Fingar at University of Michigan), mTOR (1:1,000, rabbit, Cell Signaling), β-Actin (1:5,000-10,000, mouse, Sigma-Aldrich), pS6K<sup>T389</sup> (1:1,000, rabbit, Cell Signaling), p4E-BP1<sup>T37/46</sup> (1:1,000, rabbit, Cell Signaling), pTSC2<sup>T1462</sup> (1:1,000, rabbit, Cell Signaling), S6<sup>S240/244</sup> (1:2,000, rabbit, Cell Signaling), Olig2 (1:1,000, rabbit, Cell Signaling), Olig2 (1:1,000, rabbit, Cell Signaling), mTOR (1:1,000, rabbit, Cell Signaling), Erk1/2<sup>T202/Y204</sup> (1:1,000, rabbit, Cell Signaling), Erk1/2<sup>T202/Y204</sup> (1:1,000, rabbit, Cell Signaling), pGSK-3<sup>b</sup> (1:2,000, rabbit, Cell Signaling), P120 (1:1000, mouse, BD Biosciences), Pax6 (1:1,000, rabbit, Covance), GlI1 (1:500, rabbit, Cell Signaling) and Ezh2 (1:1,000-1,2,000, rabbit, Cell Signaling) and Atoh1 (1:1000, Rabbit, Abcam, ab163874). HRP-conjugated secondary antibodies were anti-mouse (1:5,000-1:10,000, goat, BioRad) and anti-rabbit (1:5,000-1:10,000, goat, BioRad).

**Tumor-Sphere Cell Culture and Chromosome Assay**

End-stage tumors were dissected at 4°C and tissue was then transferred into DMEM medium, followed by enzymatic cell dissociation using Accutase (Innovative Cell Technologies). Cell cultures were prepared in self-renewal medium based on an established protocol (Wang et al., 2012). Cell density was quantified using a hemocytometer, (Counting Chamber, Hausser Scientific) and approximately 20,000-100,000 cells/well were plated into 6-well ultra-low attachment surface polystyrene plates (Corning) for primary tumor-sphere preparation protocol as previously described (Frappart et al., 2009). According to this protocol, cells were grown for 24 hours, treated with 0.4% KCl at 37°C, fixed in ice cold Methanol:Glacial acetic acid (3:1) solution overnight and dropped on Superfrost Plus microscope slides (Fisher Scientific). Chromosomes of metaphase cells were stained with DAPI. Cell lines analyzed at passage 1 and 2 are considered “early passage” and those analyzed at subsequent passages are considered as “late passage.”

**RT-PCR for Copy Number Analyses**

Total genomic DNAs were extracted from frozen wild-type control brain tissues, high-grade gliomas and medulloblastomas by using an AllPrep DNA/RNA Mini Kit (QIAGEN). Depending on the sample concentration, various amounts of template DNA (average 100 ng/reaction) along with the SYBR Select Master Mix (Thermo Fisher Scientific) and primers were used in RT-PCR. See primer information in Table S2. ∆CT value (CT<sub>testGene</sub> - CT<sub>reference</sub>) and then [1/CT<sub>testGene</sub>] is calculated for each sample. The average of the readings from the wild-type control tissue were set to “1” and all of the samples were calculated accordingly. β-Actin (chr5) and Gapdh (chr7), and Tfrc (chr16) were used as reference genes (internal controls). We additionally used TaqMan Copy Number Assays along with the compatible CopyCaller Software. Tfrc (chr16) was used as a reference gene in this set of analyses. The primer sets were as follows:

N-Myc

Mycn_Mm00378993_cn
Biosystems) using SYBR Select Master Mix (Applied Biosystems) and primers. See primers information in Table S2.

Approximately 300ng of RNA for each sample. RT-PCR experiments were carried out in the 7500 Real-Time PCR System (Applied Biosystems) for Gene Expression Analyses of rictor and p53

The estimated copy numbers based on β-Actin, Gapdh, and Tfrc were compared to each other to confirm the accuracy and the consistence of the copy number calculations. Then, the average of the three readings were shown in the figures.

RT-PCR for Gene Expression Analyses

CDNA synthesis, using RNA collected as described, was performed with Quantitect Reverse Transcription Kit (QIAGEN), along with approximately 300ng of RNA for each sample. RT-PCR experiments were carried out in the 7500 Real-Time PCR System (Applied Biosystems) using SYBR Select Master Mix (Applied Biosystems) and primers. See primers information in Table S2.

△CT value (CT_{testGene} - CT_{Gapdh}) and then \([1/CT]\) is calculated for each sample. The average of the readings from the Ptch1+/− model medulloblastomas was set to “100” and all of the samples were calculated accordingly. Wild-type control brain tissue and gliomas were used as negative controls for medulloblastoma samples.

Protein half-life analysis of Atoh1

A p53+/−/− medulloblastoma cell line (CKO2 L2) was treated with 200 μg/ml cycloheximide (Sigma, C7698-1G) together with vehicle (DMSO), BKM120 and MLN4924 (Selleckchem, S7109) as indicated. Then the cells were collected at indicated time points for IB assay. The Atoh1 level was quantified by densitometry analysis using ImageJ (1.50i) image processing software. The ratio of Atoh1/β-Actin was calculated and statistical analysis was performed using Prism 7 with Two-way ANOVA analysis.

Bioinformatics

Affymetrix GeneChip Mouse Genome 430 2.0 Array was used for the gene expression profiles of the glioma and medulloblastoma samples. Unsupervised hierarchical cluster analyses were used in categorization of the samples. Agilent 44K/100K cDNA and/or oligochip were used for the copy number analyses of the glioma samples. The genotypes of the MB samples used in these analyses are: p53^+/Δ (n = 3), p53^+/Δ-Δ6 Rictor^+/Δ (n = 2), p53^+/Δ-Δ6 Rictor^Δ/Δ (n = 5), p53^+/Δ-Δ5-6 Pten^+/Δ (n = 3), p53^+/Δ-Δ5-6 Pten^Δ/Δ (n = 6, three of which had germline Rictor mutation), and p53^ΔΔ-Δ5-6 Pten^+/Δ Rictor^Δ/Δ (n = 3).

Low-coverage whole genome sequencing (lgWGS) was used to infer the copy number changes in mouse medulloblastomas. The read counts per 1kb along each gene’s chromosomal region is plotted, and the copy number changes in tumor samples were calculated in comparison to matched tail DNA.

The Kaplan scanner tool in R2 was used to find the best cut-off in expression within a certain group of tumors for which the Kaplan Meier analysis gives the lowest log rank p value. This p value was corrected for multiple testing as multiple tests were performed to find the lowest p value. The plots that we showed in Figure 7 and Figure S8 were thus the plots with lowest p values. All other cut-offs gave higher p values. Of course, the cut-offs can then be different between each subgroup. However, as overall expression levels are also different between subgroups, it still makes sense to use different cut-offs. R2 is a microarray analysis and visualization platform that is freely available online: https://hgserv3r1.amc.nl/cgi-bin/r2/main.cgi.

Schematic representations of the mouse chr19 and chr7, and human chr10 were prepared based on the information in Ensembl database.

QUANTIFICATION AND STATISTICAL ANALYSIS

Kaplan-Meier survival curves were used to compare the survivorship of the mice sacrificed due to brain tumors, soft tissue sarcomas and/or other health concerns. The Mantel-Cox (Log-rank) test was used to compare the curves statistically. Anatomically comparable sections from control and mutant brains were visualized at 20X and 40X magnifications. Multiple images were captured and subjected to double-blinded analysis to measure the specific areas (i.e., cerebellar surface area) and to quantify the number of the cells using ImageJ software. At least three animals were used from each group, and two-tailed Student’s t test was used to compare the number and percentage of the different cellular populations. Fisher’s exact test was used to compare the mouse models in terms of the tumor location and tumor spectrum. Linear regression analysis was performed in RT-PCR experiments for copy number estimates comparing the readings based on two different reference genes. The coefficient of determination (R^2) and p values were calculated. Data were presented as mean ± Standard Deviation (SD) or Standard Error of the Mean (SEM), and p < 0.05 was considered to be statistically significant in all of the statistical analyses.

DATA AND SOFTWARE AVAILABILITY

The accession number for the gene expression data reported in this paper is GEO: GSE78895.
Supplemental Information

Opposing Tumor-Promoting and -Suppressive Functions of Rictor/mTORC2 Signaling in Adult Glioma and Pediatric SHH Medulloblastoma

Seçkin Akgül, Yinghua Li, Siyuan Zheng, Marcel Kool, Daniel M. Treisman, Chaoyang Li, Yuan Wang, Susanne Gröbner, Tsuneo Ikenoue, Yiping Shen, Sandra Camelo-Piragua, Gerald Tomasek, Sebastian Stark, Vinay Guduguntla, James F. Gusella, Kun-Liang Guan, Stefan M. Pfister, Roel G.W. Verhaak, and Yuan Zhu
**Figure S1**

**A**

Synteny map comparing the human chr7 with the mouse chr5, chr6, and chr11. The locations of the \( PDGFA/Pdgfa \), \( MET/Met \), and \( EGFR/Egfr \) genes are indicated in both human and mouse chromosomes.

---

**B**

Classical subtype and signature in P53-/-; Nf1-/- GEMs.

---

**C**

Mutant P53 models (44k & 100k data)

---

**D**

GBM

---

**E**

Mutant P53 models (44k & 100k data)

---

**F**

Chow et al. 2011 (24xk data)

---

**Figure S1, related to Figure 1.** p53-mutant GEM malignant gliomas are characterized by the key molecular events frequently observed in human GBMs.

(A) Synteny map comparing the human chr7 with the mouse chr5, chr6, and chr11. The locations of the \( PDGFA/Pdgfa \), \( MET/Met \), and \( EGFR/Egfr \) genes are indicated in both human and mouse chromosomes.
Heatmap representation of the copy number alterations (CNAs) in *Egfr* and *Met* genes in GEM malignant gliomas. One case (sample #3) with *Egfr* focal amplification, a characteristic event for Classical subtype, was the only case that strongly expressed the Classical subtype signature. The amplified segment roughly covers 1,080 kb with log2Ratio=4.77, as shown in the following Integrative Genomics Viewer (IGV) screenshot (C). This magnitude of amplification is common in human GBMs. There was another case that had *Egfr* gain (sample #23). It not only strongly expressed the Proneural signature, but also expressed a secondary Classical signature, as shown in Figure 1A. We used discrete copy number values (-2, -1, 0, 1, 2), representing homozygous deletion, hemizygous deletion, copy number neutral, gain, and high-level amplification. These discrete values were obtained by analyzing the segmentation distribution of each sample. The case associated with Classical subtype and another sample with Classical signature but associated with a dominant Proneural subtype are indicated with arrows. Gene deletions are shown in blue, gene amplifications are shown in red.

IGV heatmap representation of the copy number changes around a region in chr11 of the 23 GEM malignant gliomas. The location of the *Egfr* gene within this region is indicated with dashed boxes for two samples with high-level focal *Egfr* amplification (sample #3) or low-level amplification/gain (sample #23).

IGV heatmap representation of the copy number changes in human GBMs (from TCGA, D), malignant gliomas (n = 23) from GEM models used in this study (E) and malignant gliomas from GEM models from a previously published study (Chow et al., 2011) (F) are shown. Human chr10 and chr19 are highlighted with solid box. Segments of the mouse chr19 and chr7 (syntenic to human chr10q) and mouse chr7 (syntenic to human chr19) are indicated with dashed boxes.
Figure S2, related to Figure 2. Histopathological and molecular features of the p53-mutant driven malignant gliomas.

(A) Brain tumor penetrance is shown by the ratio of ‘the number of the mice sacrificed due to brain tumors’ to ‘the total number of mice analyzed within the cohorts’. Mice without brain tumors were sacrificed due to other health-concerning reasons, including soft-tissue sarcomas, paralysis, spinal cord tumors, eye problems, prolapse, dermatitis and other poor health conditions. Fisher’s exact test was used to compare the groups in terms of the frequency of mutant mice ‘with brain tumors’ versus ‘without brain tumors’.

(B) Kaplan-Meier survival curves of the mice that were sacrificed due to body tumor formation without any brain tumors or brain abnormalities. The Mantel-Cox (Log-rank) test was used to compare the survival curves statistically.

(C) Histopathological analyses of p53ΔΔ5-6 driven malignant gliomas using p53, Olig2, GFAP and Synaptophysin antibodies. Multipolar or abnormal mitoses (i, iii and xii), multinucleated giant cells (ii, iv, vi, vii and xiv), mitotic figures (x and xiii), and vascular proliferation (xv) are noted.

(D) The total number of the p53ΔΔ5-6-positive cells remaining in the germinal zone (SVZ/RMS) was quantified in 6-7 months old p53ΔΔ5-6/ΔΔ5-6 and p53ΔΔ5-6/ΔΔ5-6 RictorΔΔ mice. The proliferation percentages of the p53ΔΔ5-6-positive cells (i.e. BrdU+/p53ΔΔ5-6-positive/p53ΔΔ5-6-positive) were calculated using samples with at least 10 or more p53ΔΔ5-6-positive cells.

(E) Genotyping of the malignant glioma samples from p53ΔΔ5-6/ΔΔ5-6, p53ΔΔ5-6/ΔΔ5-6 RictorΔΔ, and p53ΔΔ5-6/ΔΔ5-6 RictorΔΔ mice. Normal brain tissue from a hGFAP-cre;p53ΔΔ5-6,ΔΔ5-6 RictorΔΔ/ΔΔ mouse was used as a positive control (Ctr) to show the PCR bands of wild-type allele and floxed allele of p53 and Rictor genes. Cre-negative normal brain tissue was used as a negative control (Ctr) for the PCR band of Cre allele.

(F) Western blot analysis of the malignant gliomas from p53ΔΔ5-6/ΔΔ5-6 (n = 4), p53ΔΔ5-6/ΔΔ5-6 RictorΔΔ (n = 8), and p53ΔΔ5-6/ΔΔ5-6 RictorΔΔ (n = 8) mice along with a normal cerebral cortex tissue (CTR) and malignant gliomas from the glioma model that harbors p53 and Pten mutations (p53ΔΔ5-6/ΔΔ5-6 PtenΔΔ, details about this model is shown in Figure S3D).

All quantification data are presented as mean ± SEM. Two-tailed Fisher’s exact test was used to compare the groups (A). The Mantel-Cox (Log-rank) test was used to compare the survival curves statistically (B). Scale bars, 25 µm.
Figure S3, related to Figure 3. Analyses of Rictor-deficient MBs in comparison with various mouse models.

(A) Western blot analysis of mTORC1 signaling pathway in p53Δ5-6/Δ5-6, p53Δ5-6/Δ5-6 RictorΔΔ, and p53Δ5-6/Δ5-6 RictorΔ/Δ MB samples along with various Ptch1+/− MBs (Ptch1+/−, p53Δ5-6/Δ5-6 Ptch1+/−, and p53R172P/Δ5-6 Ptch1+/−). Wild-type cerebellar tissue was used as a control (CTR), and two malignant glioma samples from p53Δ5-6/Δ5-6 RictorΔΔ and p53Δ5-6/Δ5-6 Pten+/Δ (last two lanes) mice were also included in the analysis.

(B) Brain tumor distribution and survival curves of p53-mutant mice with brain tumors among different cohorts. Note that mice with MBs (labeled with “blue/green-like” curves) succumbed to death earlier than the mice with malignant glioma (labeled with “pink/red-like” curves) in all cohorts and models. In addition, the penetrance of the MBs is less than 11% in all models, except for p53Δ5-6/Δ5-6 RictorΔΔ, which has up to 52% MB penetrance. Lastly, p53Δ5-6/Δ5-6 RictorΔΔ mice with malignant gliomas lived significantly longer than any of the other p53-mutant mouse models with malignant gliomas (comparison of pink/red curves), p < 0.0001.

(C and D) Genetic configuration of p53Δ5-6/Δ5-6, p53Δ5-6/Δ5-6 RictorΔΔ, and p53Δ5-6/Δ5-6 RictorΔ/Δ mice (C) and p53Δ5-6/Δ5-6 Pten+/Δ, p53Δ5-6/Δ5-6 PtenΔ/Δ, and p53Δ5-6/Δ5-6 PtenΔΔ RictorΔΔ mice (D). Floxed alleles undergo hGFAP-cre mediated recombination in radial glial cells of the developing cerebral cortex at around embryonic day 12.5 (E12.5).

(E and F) The frequency (E) and scatter plot representation (F) of malignant gliomas and MBs in the p53Δ5-6/PtenΔΔ mutant driven models with three different Rictor genotypes. Note the MB frequency is significantly increased in p53Δ5-6/Δ5-6 PtenΔΔ RictorΔΔ mice.

(G) Histopathological analysis of the malignant gliomas from p53Δ5-6/Δ5-6 PtenΔΔ RictorΔΔ and p53Δ5-6/Δ5-6 PtenΔΔ RictorΔ/Δ mice, and MBs from p53Δ5-6/Δ5-6 PtenΔΔ RictorΔΔ and p53Δ5-6/Δ5-6 PtenΔΔ RictorΔΔ mice. Note the striking difference in cellularity and Olig2 immunoreactivity between the malignant gliomas and MBs, as seen in human tumors.

The Mantel-Cox (Log-rank) test was used to compare the survival curves statistically (B). Two-tailed Fisher’s exact test was used to compare the MB frequency in different GEM models (E). Scale bars, 50 µm.
Rictor/mTORC2 signaling is essential for timely differentiation of a subset of GCPs. 

(A and B) The expression levels of Gli1, Atoh1, Boc, and Sfrp1 genes from microarray data in p53-mutant driven MBs (with or without additional Pten and Rictor mutations) and malignant gliomas, previously published GEM models of WNT, SHH, and Group 3 MBs, GCPs, and normal cerebellar tissues were compared. p53-mutant driven MBs with possible normal tissue contamination are labeled as "p53-mut MB (contam.)". p-values of several group comparisons are shown in (B).

(C) Gene expression levels of Gli1, Gli2, Atoh1, and Sfrp1 from microarray data were examined in relation to Rictor status in p53-mutant driven MBs.

(D and E) Control and mutant mice at P16 were injected with BrdU and analyzed two hours later. The total surface area (mm$^2$) (D) and the total number of BrdU$^+$ proliferating cells (E) were calculated for each of the wild-type control and mutant cerebella.

(F) Several group comparisons related to Figure 4I are presented with a table.

(G-L) P22 control and mutant mice were injected with BrdU and sacrificed two hours later. High magnification views of Folia-5/6 (G), Folia-9/10a (H), and Folia-10b (I) illustrate the BrdU$^+$ proliferating cells, Pax6$^+$ neural lineage cells, and NeuN$^+$ differentiated neurons in P22 cerebella. Two types of Rictor-deficient mutant mice are highlighted by red dashed boxes.

(J-L) The total number of the Pax6$^+$ cells that were located in ML (J) or proliferating in EGL-associated areas (K) was quantified in three folia (Folia-5/6, Folia-9/10a, and Folia-10b). p-values for several comparisons are shown in (L).

All quantification data presented as mean ± SEM. Unpaired Student’s t-test was used to compare the groups statistically. Scale bars, 100 µm. 

EGL, External Granular Layer; ML, Molecular Layer; IGL, Internal Granular Layer.
Figure S5, related to Figure 5. Inhibition of PI3K/Akt signaling resembles Rictor deficiency phenotype in developing mouse brain.

(A) P8 control and Rictor\(^{\Delta/\Delta}\) cerebella were co-stained with pAkt\(^{S473}\) and lineage-specific markers NeuN (granule neurons), GFAP (Bergmann glial cells), and Calbindin (CalB, Purkinje cells). DAPI labels the nuclei. Arrows indicate the differentiated neurons with robust pAkt\(^{S473}\) expression in IGL.

(B) pAkt\(^{S473}\) was co-labeled with NeuN (granule neurons) in adult wild-type control cerebellum. DAPI is shown in blue.

(C-E) Wild type mice were treated with vehicle or BKM120 (10\(\mu\)M) from P8 to P16. Analyses were performed at P16.

(C) Body weights of vehicle- or BKM120-treated mice were measured daily between P8-P16.

(D and E) Representative whole-mount images of brains collected from vehicle- or BKM120-treated brains (D), and their weight at P16 (E).

(F-H) Body weights (F) and brain weights (H) of the wild-type control, p53\(^{+/-}\)Rictor\(^{\Delta/\Delta}\), and p53\(^{+/-}\)Rictor\(^{\Delta/\Delta}\) mice at P8, P16, P22 and, 4-months (P120). G, Whole-mount images of brains collected from 4-months old wild-type control, p53\(^{+/-}\)Rictor\(^{\Delta/\Delta}\), and p53\(^{+/-}\)Rictor\(^{\Delta/\Delta}\) mice.

(I and J) Total Ki67\(^{+}\) cell number was quantified in all EGLs (I) and only in Folia-6&7 (J), related to Figure 5C.

(K and L) Representative H&E staining of cerebella from vehicle- or BKM120-treated mice. Areas marked with Roman numbers indicate Folia-6, Folia-7, and Folia-8 (K). High magnification images of marked areas in F-6a/6b, F-6b/7, and F-7/8 are also shown (L). Arrowheads indicate the retained cells in EGL.

(M) p53\(^{+/-}\)medulloblastoma cell line was treated with DMSO and BKM120 (0.1\(\mu\)M) for different time periods as indicated. Then, CellTiter-Glo luminescent cell viability analysis was performed. For each time point, the ratio of BKM120 group/DMSO group was calculated.

(N) p53\(^{+/-}\)medulloblastoma cell line was treated with BKM120 (0.1\(\mu\)M) for different time periods as indicated. Then, the cells were collected and subjected to -qPCR analysis to determine Atoh1 mRNA levels. Four repeated experiments were analyzed.

All quantification data presented as mean ± SEM. Unpaired Student’s t-test was used to compare the groups statistically in (C, E, F, H, I, J). Scale bars, 1 mm (D and G), 250 \(\mu\)m (K), 100 \(\mu\)m (A), and 50 \(\mu\)m (B and L). EGL, External Granular Layer; ML, Molecular Layer; IGL, Internal Granular Layer.
Figure S6

A. p53Δ/Δ • p53Δ/Δ:RictorΔ/Δ
B. p53Δ/Δ • p53Δ/Δ:RictorΔ/Δ
C. p53Δ/Δ • p53Δ/Δ:RictorΔ/Δ

D. P60
Cluster 1
Cluster 2

E. Pch1 Status
Wild type or Het
Mutation + Het deletion
Homo deletion

F. G3: p53Δ/Δ;PtenΔ/Δ;RictorΔ/Δ (N-Myc low-level amplification/gain)

G. G1: p53Δ/Δ;PtenΔ/Δ;RictorΔ/Δ

H. Chr13
Pch1

I. Chr19
Pten

J. G3: p53Δ/Δ;PtenΔ/Δ;RictorΔ/Δ

K. G3: p53Δ/Δ;PtenΔ/Δ;RictorΔ/Δ

L. G3: p53Δ/Δ;PtenΔ/Δ;RictorΔ/Δ

M. N-Myc and/or chr12
Gli2 and/or chr1
Pch1 and/or chr13
Pten and/or chr19

<table>
<thead>
<tr>
<th></th>
<th>N-Myc and/or chr12</th>
<th>Gli2 and/or chr1</th>
<th>Pch1 and/or chr13</th>
<th>Pten and/or chr19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rictor+Δ</td>
<td>0% (0/3)</td>
<td>0% (0/3)</td>
<td>67% (2/3)</td>
<td>67% (2/3)</td>
</tr>
<tr>
<td>Rictor-Δ</td>
<td>17% (1/6)</td>
<td>20% (1/5)</td>
<td>0% (0/4)</td>
<td>0% (0/4)</td>
</tr>
<tr>
<td>RictorΔ</td>
<td>67% (4/6)</td>
<td>33% (1/3)</td>
<td>67% (4/6)</td>
<td>60% (3/5)</td>
</tr>
<tr>
<td>TOTAL</td>
<td>33% (5/15)</td>
<td>18% (2/11)</td>
<td>46% (6/13)</td>
<td>42% (5/12)</td>
</tr>
</tbody>
</table>

* One additional sample has an indel mutation in Pten gene.
Figure S6, related to Figure 6. *p53*-mutant driven MBs share critical features of TP53-mutant SHH-MBs in humans

(A–C) The total number of BrdU+ cells (A) and p53Δ5-6-positive cells (B) over three time points – P16, P22, and P60 – were quantified. The percentage of proliferating p53Δ5-6-positive cells among the entire proliferating population (BrdU+p53Δ5-6-positive/BrdU+) was calculated (C).

(D) Examples of clustered BrdU+p53Δ5-6-positive cells in p53Δ5-6Δ5-6 RictorΔΔ cerebella at P60. Arrows indicate BrdU+p53Δ5-6-positive cells, arrowheads indicate BrdU−p53Δ5-6 cells.

(E) Frequency of *Ptch1* bi-allelic inactivation across different mouse MB models. Dark blue bars indicate the samples with homozygous *Ptch1* deletion while light blue bars indicate the samples with concurrent heterozygous *Ptch1* deletion and *Ptch1* mutation. White bars indicate samples with at least one intact *Ptch1* allele (i.e. wild type or heterozygous *Ptch1*).

(F) Low-coverage whole genome sequencing (lcWGS) plots depicting the copy number alterations (CNAs) in chr12, chr1, and the entire genome of *p53*-mutant driven MBs. The low-level N-Myc amplification/gain (sample G3), chr12 gain (samples C4 and E1), and low-level Gli2 amplification/gain (sample B4) are colored in red. X-axes specify the location within each chromosome. Y-axes indicate the number of read per 1 kb normalized to total reads. This parameter is shown as a ratio of tumor versus control tissue. Baseline is shown with a red line across the plots. Red frames label the chromosomal regions with gains/amplifications. (G-L) lcWGS plots of whole genome or chr13 and chr19 in two *p53*-mutant driven mouse MBs with *Rictor* deletions. X-axes specify the location within each chromosome. Y-axes indicate the number of read per 1 kb normalized to total reads. This parameter is shown as a ratio of tumor versus control tissue. Baseline is shown with a red line across the plots. Blue shades and frames label the chromosomal regions with losses while the red shades and frames label the chromosomal regions with gains/amplifications. chr13 and chr19 are framed by blue and/or red rectangles in (G and J), and they are shown in higher magnification (H and K for chr13 and I and L for chr19). The approximate locations of *Ptch1* (H and K) and *Pten* (I and L) genes are indicated with arrows.

(M) The frequencies of each copy number alterations exemplified in (F-L) were calculated and presented in relation to their *Rictor* genotype. The actual numbers of the events are shown, and the ratios are presented as percentages in parentheses. Fisher’s exact test was used to compare the groups statistically in (E). Scale bars, 50 µm. EGL, External Granular Layer.
**Figure S7**

(A and B) Karyotyping assay was performed to examine the overall chromosomal structure and chromosome number in early-passage (passage number ≤ 2) \( p53^{Δ5-6/Δ5-6} \text{Rictor}^{Δ/Δ} \) MB cell lines. Head-to-head fusions (i, ii, iv, v and vi), head-to-tail fusions or translocations (iv) and centromere loss (iii) are pointed with red arrowheads (A). The chromosome numbers were quantified in \( p53^{Δ5-6/Δ5-6} \text{Rictor}^{Δ/Δ} (n = 9) \) and \( p53^{Δ5-6/Δ5-6} \text{Rictor}^{Δ/Δ} (n = 1) \) MB cell lines. The cells with clear aneuploidy are shown with red dots while others with diploid genomes are shown in black (B).

(C) Schematic representation of the opposing roles of Rictor/mTORC2 signaling in \( p53^{Δ5-6} \)-mutant driven brain tumorigenesis.

**Figure S7, related to Figure 6.** \( p53 \)-mutant driven MBs display distinct chromosomal and genomic features. (A and B) Karyotyping assay was performed to examine the overall chromosomal structure and chromosome number in early-passage (passage number ≤ 2) \( p53^{Δ5-6/Δ5-6} \text{Rictor}^{Δ/Δ} \) MB cell lines. Head-to-head fusions (i, ii, iv, v and vi), head-to-tail fusions or translocations (iv) and centromere loss (iii) are pointed with red arrowheads (A). The chromosome numbers were quantified in \( p53^{Δ5-6/Δ5-6} \text{Rictor}^{Δ/Δ} (n = 9) \) and \( p53^{Δ5-6/Δ5-6} \text{Rictor}^{Δ/Δ} (n = 1) \) MB cell lines. The cells with clear aneuploidy are shown with red dots while others with diploid genomes are shown in black (B). (C) Schematic representation of the opposing roles of Rictor/mTORC2 signaling in \( p53^{Δ5-6} \)-mutant driven brain tumorigenesis.
**Figure S8, related to Figure 7.** RICTOR expression, but not other components of mTORC2 and mTORC1, is correlated with opposite clinical outcomes in pediatric SHH-MBs versus adult non-G-CIMP primary GBMs. 

(A, D, and G) Scatter plot representation of SIN1 (MAPKAP1) (A), MTOR (D), and RPTOR (G) expression among the pediatric (infant and childhood) and adult SHH-MB samples.

(B and C) Overall survival probability of the pediatric (B) and adult (C) patients with SHH-MBs in relation to SIN1 expression.

(E and F) Overall survival probability of the pediatric (E) and adult (F) patients with SHH-MBs in relation to MTOR expression.

(H and I) Overall survival probability of the pediatric (H) and adult (I) patients with SHH-MBs in relation to RPTOR expression.

(J) Overall survival probability of the non-G-CIMP GBM patients (with less than 7 months follow-up) based on their RICTOR expression.

(K-M) Overall survival probability of the GBM patients based on their SIN1 (K), MTOR (L), and RPTOR (M) expression.

Anova test was used to compare the groups statistically in (A, D and G). Multiple corrected log-rank tests between pairs of groups are used for comparisons of survival curves in (B, E, F and H-M). The individual data sets are initially scanned to find the cut-off in expression that results in the lowest p-value between high and low expression values.